Amgen Inc. (BIT:1AMGN)

Market Cap	125.90B
Revenue (ttm)	31.57B
Net Income (ttm)	5.49B
Shares Out	n/a
EPS (ttm)	10.12
PE Ratio	22.94
Forward PE	12.75
Dividend	6.25 (2.67%)
Ex-Dividend Date	May 15, 2025

Volume	8
Average Volume	94
Open	241.95
Previous Close	246.60
Day's Range	236.00 - 241.95
52-Week Range	233.00 - 337.65
Beta	n/a
RSI	34.30
Earnings Date	May 1, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD